Marcela V. Maus, M.d.,ph.d.

This early-phase study tests a new type of CAR T-cell therapy that targets two proteins (CD79b and CD19) on lymphoma cells. It is for people with Non-Hodgkin lymphoma that has come back or not responded to other treatments. The main goals are to check safety and find the right do…

This study follows about 45 adults who have already received CAR T cells in earlier phase 1 trials. Researchers will track their health for years to check for long-term side effects, how long the treatment lasts, and overall survival. The goal is to better understand the lasting …